Insights Into Acute Lymphoblastic Leukemia Northeast (ALL)

Perspectives on current treatment practices in the northeast region of the US regarding adult and AYA ALL, the role of MRD, and current treatment practices regarding relapsed disease

Northeast – August 24, 2020
Purchase Report

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

Insights on the following therapies were obtained

  • pegaspargase
  • asparaginase
  • imatinib
  • dasatinib
  • ponatinib
  • blinatumomab
  • inotuzumab ozogamicin
  • chimeric antigen receptor (CAR) T-cell therapy

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated roundtable discussion focusing on treatment of ALL in the northeast region of the US
  • Attendees of the roundtable represented community oncologists from Maryland, New Jersey, New York, and Pennsylvania
  • Disease state and data presentations were developed in conjunction with a medical expert from MD Anderson Cancer Center
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.